查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球風濕病治療市場 2023-2030
市場調查報告書
商品編碼
1351027

全球風濕病治療市場 2023-2030

Global Rheumatology Therapeutics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

預計在預測期內（2023-2030年）全球市場將以3.2%的年複合成長率成長。治療藥物用於減緩某些自體免疫性風濕性疾病的進展，例如風濕性關節炎（RA）。 RA在全球的盛行率不斷上升，促進了新型治療藥物的推出，而針對高成本治療產品的有利翻新政策是推動市場成長的一些因素。根據美國國立衛生研究院 (NIH) 的數據，2023 年 5 月，女性患風濕性關節炎的比例高於男性，女性終生患風濕性關節炎的風險為 3.6%，而男性為 1.7%。 RA 風險也隨著年齡的成長而增加，發病高峰在 65 歲至 80 歲之間。此外，新型生物藥物上市率的上升、學名藥的批准增加和滲透率的不斷提高，為風濕病治療市場帶來了盈利機會。例如，2022 年6 月，安進宣布FDA 批准Rituxan (R) 的生物相似藥RIABNI (TM) (rituximab-arrx) 與甲氨蝶呤聯合治療患有中度至重度活動性類風濕性關節炎( RA) 的成人患者。對一種或多種腫瘤壞死因子 (TNF) 拮抗劑治療反應不足。

細分市場前景

全球風濕病治療市場按藥物類型、疾病適應症、類別和分銷管道進行細分。根據藥物類型，市場細分為緩解疾病的抗風濕藥、非類固醇類抗發炎藥、皮質類固醇、降尿酸藥等。根據疾病適應症，市場細分為類風濕性關節炎、骨關節炎、痛風、乾癬性關節炎和僵直性脊椎炎。根據類別，市場分為處方藥和非處方藥。此外，根據分銷管道，市場分為醫院藥房、零售藥房和網路藥房。在疾病適應症中，由於基於成簇規則間隔短回文重複序列（CRISPR）/Cas9的基因組編輯、RNA干擾、PROTAC等新技術的發展，預計類風濕性關節炎細分市場將佔據相當大的市場佔有率（蛋白水解靶向嵌合體）和基於人工智慧（AI）的藥物設計能夠篩選標靶療法。

疾病緩解抗風濕藥物 (DMARD) 預計將在全球風濕病治療市場中佔據相當大的佔有率

在該藥物類型中，該細分市場預計將在全球風濕病治療市場中佔據相當大的佔有率。這一細分市場的成長歸因於 DMARD 利用率的增加以及全球 RA 發生率的上升。例如，根據國家生物技術資訊中心的數據，2022 年 6 月，美國和北歐其他西方國家的 RA 年發生率約為每 10 萬人中 40 例。由於人們對 RA 治療方案的認知激增。

區域展望

全球風濕病治療市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於類風濕性關節炎的盛行率不斷增加，人們對該疾病的認知不斷提高，並且患病率的增加加上先進的類風濕性關節炎療法的採用，預計亞太地區將佔據顯著的市場佔有率。市場成長。主要市場參與者包括中外製藥有限公司、Dr Reddy's Laboratories Ltd. LG Chem、Lupin Ltd、Taisho Pharmaceutical Holdings Co., Ltd.等。

北美地區預計全球風濕病治療市場年複合成長率顯著成長

在所有地區中，北美地區預計在預測期內將以相當大的年複合成長率成長。該區域市場的成長歸因於人們對風濕病早期診斷和治療的認知不斷提高，以及擴大使用 DMARD 進行治療。此外，新型生物藥物上市的增加、學名藥的批准增加和滲透率的不斷提高，為風濕病治療市場參與者帶來了盈利機會。例如，2023 年7 月，Biocon Ltd. 的子公司Biocon Biologics Ltd (BBL) 宣布，經過在歐洲使用5 年和在加拿大使用兩年後，HULIO (R) (adalimumab-fkjp) 注射劑（一種生物學名藥） Humira (R)（阿達木單抗）現已可供美國患者使用。

市場參與者展望

服務全球風濕病治療市場的主要公司包括： F. Hoffmann-La Roche Ltd.、Johnson & Johnson Private Ltd.、Merck & Co., Inc.、Novartis AG、Pfizer Inc.等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023 年 1 月，吉利德科學公司 (Gilead Sciences, Inc.) 和 EVOQ Therapeutics, Inc. 簽訂許可協議進行合作，推進 EVOQ 用於治療類風濕性關節炎 (RA) 和狼瘡的專有技術。 EVOQ 的 NanoDisc 技術旨在實現疾病特異性抗原的淋巴靶向遞送，並有可能改變自體免疫疾病的治療模式。

報告涵蓋：

  • 2022年市場價​​值數據分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球風濕病治療市場的主要公司。根據現有數據，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Merck & Co., Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Novartis AG
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Pfizer Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按藥物類型分類的全球風濕病治療市場
    • 緩解疾病的抗風濕藥物
    • 非類固醇抗發炎藥
    • 皮質類固醇
    • 降尿酸藥物
    • 其他
  • 按疾病適應症分類的全球風濕病治療市場
    • 類風濕關節炎
    • 骨關節炎
    • 痛風
    • 銀屑病關節炎
    • 僵直性脊椎炎
  • 全球風濕病治療市場按類別
    • 處方
    • 場外交易 (OTC)
  • 按分銷管道分類的全球風濕病治療市場
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurinia Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Private Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi, Genentech, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • UCB S.A.
Product Code: OMR2027627

Title: Global Rheumatology Therapeutics Market Size, Share & Trends Analysis Report by Drug Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis), by Category (Prescription and Over-the-Counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy),Forecast Period (2023-2030).

The global market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). Therapeutic drugs are used to slow down the progression of certain autoimmune rheumatic diseases such as rheumatic arthritis (RA). The increasing prevalence of RA globally has bolstered the launch of novel therapeutic agents and favorable refurbishment policies for high-cost treatment products are some of the factors driving the market growth. According to the National Institute of Health (NIH), in May 2023, rheumatic arthritis is more prevalent in women compared to men, with a lifetime risk of rheumatic arthritis of 3.6% in women compared to 1.7% in men. RA risk also increases with age, with a peak incidence between age 65 to 80 years of age. Furthermore, the rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market. For instance, in June 2022, Amgen announced that FDA approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Segmental Outlook

The global rheumatology therapeutics market is segmented on the drug type, disease indication, category, and distribution channel. Based on the drug type, the market is sub-segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. Based on the disease indication, the market is sub-segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and ankylosing spondylitis. Based on the category, the market is bifurcated into prescription and OTC. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy and online pharmacy. Among the disease indication, the rheumatoid arthritis sub-segment is anticipated to hold a considerable share of the market owing to the development of novel technologies such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based genome editing, RNA interference, PROTACs (proteolysis-targeted chimeras), and artificial intelligence (AI)-based drug design enable the screening of therapies targeting.

The Disease-modifying Anti-rheumatic Drugs (DMARDs) Sub-Segment is Anticipated to Hold a Considerable Share of the Global Rheumatology Therapeutics Market

Among the drug type, the sub-segment is expected to hold a considerable share of the global rheumatology therapeutics market. The segmental growth is attributed to the increased utilization of DMARD coupled with the rising incidence of RA around the globe. For instance, according to the National Center for Biotechnology Information, in June 2022, the annual incidence of RA in the US and other Western nations of northern Europe is about 40 per 100,000 persons. Owing to a surge in awareness related to treatment options available for RA.

Regional Outlook

The global rheumatology therapeutics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market, owing to the increasing prevalence of rheumatoid arthritis, increasing awareness about the disorder, and increasing prevalence combined with the adoption of advanced rheumatoid arthritis therapeutics is expected to drive market growth. The key market player includes Chugai Pharmaceutical Co., Ltd., Dr Reddy's Laboratories Ltd. LG Chem, Lupin Ltd, Taisho Pharmaceutical Holdings Co., Ltd., and others.

The North America Region is Expected to Grow at a Significant CAGR in the Global Rheumatology Therapeutics Market

Among all regions, the North America region is anticipated to grow at a considerable CAGR over the forecast period. The regional market growth is attributed to the growing awareness regarding the early diagnosis and treatment of rheumatology disease and the increasing use of DMARD's for treating. Furthermore, the rise in launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players. For instance, in July 2023, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., announced that after 5 years of use in Europe and two years in Canada, HULIO® (adalimumab-fkjp) injectable, a biosimilar to Humira® (adalimumab), is now accessible to patients in the US.

Market Players Outlook

The major companies serving the global rheumatology therapeutics market include: F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. collaborated along with a licensing agreement to advance EVOQ's proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ's NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global rheumatology therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Merck & Co., Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rheumatology Therapeutics Market by Drug Type
    • 4.1.1. Disease-Modifying Anti-Rheumatic Drugs
    • 4.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 4.1.3. Corticosteroids
    • 4.1.4. Uric Acid Drugs
    • 4.1.5. Others
  • 4.2. Global Rheumatology Therapeutics Market by Disease Indication
    • 4.2.1. Rheumatoid Arthritis
    • 4.2.2. Osteoarthritis
    • 4.2.3. Gout
    • 4.2.4. Psoriatic Arthritis
    • 4.2.5. Ankylosing Spondylitis
  • 4.3. Global Rheumatology Therapeutics Market by Category
    • 4.3.1. Prescription
    • 4.3.2. Over-the-Counter (OTC)
  • 4.4. Global Rheumatology Therapeutics Market by Distribution Channel
    • 4.4.1. Hospital Pharmacy
    • 4.4.2. Retail Pharmacy
    • 4.4.3. Online Pharmacy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. AstraZeneca plc
  • 6.4. Aurinia Pharmaceuticals Inc.
  • 6.5. Boehringer Ingelheim International GmbH
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Eli Lilly
  • 6.8. F. Hoffmann-La Roche Ltd.
  • 6.9. Gilead Sciences, Inc.
  • 6.10. Janssen Pharmaceuticals, Inc.
  • 6.11. Johnson & Johnson Private Ltd.
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sanofi, Genentech, Inc.
  • 6.14. Takeda Pharmaceutical Company Ltd.
  • 6.15. UCB S.A.

LIST OF TABLES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CORTICOSTEROIDS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL URIC ACID DRUGS FOR RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2022 VS 2030 (%)
  • 7. GLOBAL RHEUMATOID ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL GOUT THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANKYLOSING SPONDYLITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022 VS 2030 (%)
  • 13. GLOBAL RHEUMATOLOGY THERAPEUTICS BY PRESCRIPTION MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL RHEUMATOLOGY THERAPEUTICS BY OVER-THE-COUNTER (OTC) MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 16. GLOBAL RHEUMATOLOGY THERAPEUTICS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RHEUMATOLOGY THERAPEUTICS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL RHEUMATOLOGY THERAPEUTICS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 21. US RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. UK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2022-2030 ($ MILLION)